Skip to main content
. Author manuscript; available in PMC: 2019 Feb 15.
Published in final edited form as: Cell Signal. 2018 Apr 17;47:142–150. doi: 10.1016/j.cellsig.2018.04.004

Fig. 2.

Fig. 2.

Effects of RANKL and TRAIL on NF-κB activation in HASMCs. Smooth muscle cells were treated for 72 h with RANKL (0–25 ng/ml), TRAIL (0–25 ng/ml), or a combination of both ligands (see key below). Cells were then monitored by Western blotting for activation of NF-κB as follows: (A) p52/p100 ratio; and (B) Phosphop65/ p65 ratio. Histograms represent fold change in band intensity relative to untreated controls. Blots are representative. *P ≤.05 versus 0 ng/ml RANKL (or control). Key: 5R, 5 ng/ml RANKL; 25R, 25 ng/ml RANKL; 5T, 5 ng/ml TRAIL.